Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Limertinib vs Gefitinib in First-Line EGFR+ NSCLC
NCT04143607Phase 3Active, not recruiting
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Start
- Jul 2019
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of limertinib in non-small cell lung cancer (NSCLC), sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd.. Started Jul 2019; status: active, not recruiting.
02
Drugs
limertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04143607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04143607.